Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
DelveInsight's "Fuchs Endothelial Corneal Dystrophy Pipeline Insight 2026" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Fuchs Endothelial Corneal Dystrophy ...
CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Important insights into the mechanisms behind Fuchs endothelial corneal dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. A new ...
LONDON and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of ...
DelveInsight's “Persistent Corneal Epithelial Defects Pipeline Insight 2025” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Persistent Corneal Epithelial Defects ...
OKYO Pharma Limited announced promising results from a Phase 2 clinical trial of urcosimod, a treatment for neuropathic corneal pain (NCP), where 75% of patients receiving 0.05% urcosimod reported ...
LONDON and NEW YORK, Jan. 23, 2026), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results